Ocuphire Pharma Investor Update
RM
25
Summary of Safety Findings
Nyxol was Well Tolerated with a Favorable Safety Profile
There were no deaths, serious AEs, or withdrawals due to AEs
●
• 48 of 244 (20%) Nyxol treated subjects reported 101 AEs
All treatment related AEs were mild in severity
●
●
●
●
-
The only AE occurring in ≥ 5% of subjects treated with Nyxol, was
conjunctival hyperemia (11% Nyxol vs. 0% placebo)
Less than 1% of subjects reported instillation site discomfort, pain, or irritation
Conjunctival hyperemia was observed to be mild and transient
Visual acuity (distance and near) was not adversely affected by Nyxol
Over 300 subjects have been treated with Nyxol and evaluated at 24-hours in
the MIRA trials satisfying regulatory requirements for drug safety exposure
for the acute RM indication
-
Source: MIRA-3 Table 14.3.1.1; MIRA-3 Table 14.3.1.2.2; MIRA-3 Table 14.3.3.2 (Safety Population).
Ocuphire
PHARMAView entire presentation